Skip to main content
. 2016 May 17;1(3):e000045. doi: 10.1136/esmoopen-2016-000045

Figure 3.

Figure 3

PFS of patients with colorectal cancer with grade 2–3 bevacizumab-induced HTN and without bevacizumab-related HTN (p<0.001). HTN, hypertension; PFS, progression-free survival.